199 related articles for article (PubMed ID: 19394133)
1. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
Khan S; Panicker J; Roosen A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ; Kessler TM
Eur Urol; 2010 May; 57(5):891-6. PubMed ID: 19394133
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
Giannantoni A
Eur Urol; 2010 May; 57(5):896. PubMed ID: 19394135
[No Abstract] [Full Text] [Related]
3. Editorial comment on: complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
Kilinc M; Guven S
Eur Urol; 2010 May; 57(5):895-6. PubMed ID: 19394134
[No Abstract] [Full Text] [Related]
4. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
[TBL] [Abstract][Full Text] [Related]
5. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
[TBL] [Abstract][Full Text] [Related]
6. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
Rovner E; Kennelly M; Schulte-Baukloh H; Zhou J; Haag-Molkenteller C; Dasgupta P
Neurourol Urodyn; 2011 Apr; 30(4):556-62. PubMed ID: 21351127
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
10. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Kuo HC; Liao CH; Chung SD
Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
Lee JC; Yokoyama T; Hwang HJ; Arimitsu H; Yamamoto Y; Kawasaki M; Takigawa T; Takeshi K; Nishikawa A; Kumon H; Oguma K
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):201-11. PubMed ID: 17692094
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R
BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928
[TBL] [Abstract][Full Text] [Related]
13. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.
Kalsi V; Apostolidis A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ
Eur Urol; 2008 Jul; 54(1):181-7. PubMed ID: 18191323
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin as a treatment for refractory overactive bladder.
Harris S; Rizzolo D
JAAPA; 2016 Feb; 29(2):1-4. PubMed ID: 26818640
[TBL] [Abstract][Full Text] [Related]
15. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ
J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
[TBL] [Abstract][Full Text] [Related]
16. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
17. [Input from a specialized nurse consultation in the management of detrusor overactivity treated with intradetrusor injections of botulinum toxin in urology department. Pilot study].
Le Gal S; Safsaf A; Galliot I; Catovic B; Grise P
Prog Urol; 2010 Sep; 20(8):584-9. PubMed ID: 20832036
[TBL] [Abstract][Full Text] [Related]
18. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
[No Abstract] [Full Text] [Related]
19. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
Denys P; Le Normand L; Ghout I; Costa P; Chartier-Kastler E; Grise P; Hermieu JF; Amarenco G; Karsenty G; Saussine C; Barbot F;
Eur Urol; 2012 Mar; 61(3):520-9. PubMed ID: 22036776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
